mdxg stock quote Overview and Investment Analysis

MDXG stock quote is a publicly traded company that offers a range of products for wound care and other medical applications.

MDXG has a strong presence in the wound care market with its flagship product, Acticoat, being a leading antimicrobial dressing.

The company has reported steady revenue growth over the years, with a significant increase in sales of its Acticoat product.

Investors may be interested in MDXG stock quote for its potential for long-term growth in the wound care market.

The company's focus on innovation and research and development has led to the introduction of new products and technologies.

You might like: Michiline Stock Market Quote

In 2023, MiMedx Group's sales reached 321.48 million USD, a 20.03% increase from 2022. This significant growth is a positive sign for the company's financial health.

The company's gross profit on sales also saw a notable increase in 2023, reaching 264.99 million USD, a 21.95% rise from the previous year. This indicates that MiMedx Group is efficiently managing its costs and maintaining its profit margins.

Here's a breakdown of MiMedx Group's financial data for 2023:

MiMedx Group's revenue estimates for 2025 are also looking promising, with an average estimate of 377 million USD among analysts. This is a significant increase from the previous year's revenue.

Income Statements (USD) provide a clear picture of a company's financial performance over time. The data shows that sales have been steadily increasing, with a notable spike in 2023, reaching 321.48 million USD.

The change in sales percentage over the years is also worth noting. In 2023, sales increased by 20.03%, followed by a 3.57% increase in 2022. In 2017, sales jumped by 31.07%. On the other hand, sales decreased by 17.05% in 2020.

Gross profit on sales has also been on the rise, with a 21.95% increase in 2023. The gross profit margin has been steadily increasing over the years, with a notable jump in 2017, reaching 33.10%. In 2018, the gross profit margin was 12.73%.

Operating income, however, has been a mixed bag. In 2023, operating income was 37.12 million USD, but it was a significant decrease from 2022, when it was -24.97 million USD. In 2017, operating income was 46.22 million USD.

Here's a summary of the key financial metrics:

Income before tax and income after tax have also been fluctuating, with significant changes in some years. In 2023, income before tax was 30.63 million USD, but it was a significant decrease from 2022, when it was -29.99 million USD.

Estimates in USD are a crucial aspect of financial data. Revenue estimates for MiMedx Group are expected to be $377 million in 2025, $428 million in 2026, and $472 million in 2027.

The number of analysts providing revenue estimates has decreased from 5 to 4 between the previous quarter and the current quarter. The average revenue estimate for the current quarter is $86 million, down from $89 million in the previous quarter.

The average earnings estimate for 2025 is $0.058 USD, according to 4 analysts. This is a decrease from the average earnings estimate of $0.072 USD in the previous quarter.

Here is a table summarizing the average revenue and earnings estimates for MiMedx Group:

The number of analysts providing revenue estimates has decreased from 5 to 3 between the previous quarter and the next year. The average earnings estimate for 2026 is $0.430 USD, according to 3 analysts.